The Practice of Compounding, Associated Compounding Regulations, and the Impact on Dermatologists.
Level 5 - mechanism / opinion, no new human data
Narrative review and regulatory overview without systematic search or primary empirical data.
What was done
The authors reviewed historical context, federal legislation (the 2013 Drug Quality and Security Act), and state regulations governing pharmaceutical compounding. They analyzed regulatory distinctions between 503(a) traditional pharmacies and 503(b) outsourcing facilities, assessed impacts on in-office dermatologic compounding, and developed a decision algorithm for practicing dermatologists.
What was found
The abstract reports historical data regarding the 2012 New England Compounding Center fungal meningitis outbreak that infected 800 people and caused several fatalities. Following the 2013 Drug Quality and Security Act, oversight increased for 503(a) pharmacies, 503(b) outsourcing facilities were established, and federal/state policies increasingly restricted physicians from performing low-risk, in-office compounding. No empirical or clinical outcome numbers are reported.
Why it matters
It clarifies the evolving regulatory landscape surrounding medication compounding, providing dermatologists with guidance to navigate legal constraints when prescribing or mixing medications.
Limits
The article is a narrative review and policy overview, not an empirical study or systematic review. It lacks primary quantitative clinical data, safety metrics, or formal assessment of practice outcomes.
Cited by
- supports Section 503B compounding pharmacies were created under federal legislation during the Obama administration.